X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
Details:
SP-2577 (seclidemstat) is an oral LSD1 inhibitor, small molecule drug candidate. It is being evaluated in phase 1 /2 clinical trials for the treatment of Ewing sarcoma.
Lead Product(s): Seclidemstat,Topotecan Hydrochloride,Cyclophosphamide
Therapeutic Area: Oncology Product Name: SP-2577
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2024
Details:
Preclinical results demonstrated that topotecan treatment enhanced VCN-01 oncolytic activity against retinoblastoma. VCN-01, an oncolytic adenovirus expressing hyaluronidase developed by Albumin Shield™ technology.
Lead Product(s): VCN-01,Topotecan Hydrochloride
Therapeutic Area: Oncology Product Name: VCN-01
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2022
Details:
SP-2577 (seclidemstat) is a novel oral, reversible, targeted LSD1 inhibitor that affects gene expression currently being studied in Phase 1/2 clinical studies for the treatment of solid and hematologic cancers where LSD1 is implicated in disease progression.
Lead Product(s): Seclidemstat,Topotecan Hydrochloride,Cyclophosphamide
Therapeutic Area: Oncology Product Name: SP-2577
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 22, 2022
Details:
Seclidemstat is a novel, oral, reversible inhibitor of the lysine-specific histone demethylase 1 enzyme (LSD1), an enzyme that has been shown to play a key role in the development and progression of certain cancers.
Lead Product(s): Seclidemstat,Topotecan Hydrochloride,Cyclophosphamide
Therapeutic Area: Oncology Product Name: SP-2577
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 29, 2021
Details:
Salarius lead candidate, SP-2577 (seclidemstat) is currently advancing a Phase 1/2 dose-expansion clinical trial,used as a treatment for pediatric cancers, sarcomas, and other cancers.
Lead Product(s): Seclidemstat,Topotecan Hydrochloride,Cyclophosphamide
Therapeutic Area: Oncology Product Name: SP-2577
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2021
Details:
Seclidemstat (SP-2577), Salarius’ lead drug candidate, has a differentiated mechanism of action that gives it potent activity in sarcomas compared to another LSD1 inhibitor used in pediatric cancers, sarcomas and other cancers with limited treatment options.
Lead Product(s): Seclidemstat,Topotecan Hydrochloride,Cyclophosphamide
Therapeutic Area: Oncology Product Name: SP-2577
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Nationwide Children’s Hospital
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 07, 2021
Details:
The grant will support development of lead drug candidate, Seclidemstat (SP-2577) is a novel, oral tablet, reversible inhibitor of lysine-specific histone demethylase 1 (LSD1), an enzyme that plays a key role in the development and progression of several cancers.
Lead Product(s): Seclidemstat,Topotecan Hydrochloride,Cyclophosphamide
Therapeutic Area: Oncology Product Name: SP-2577
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cancer Prevention and Research Institute of Texas
Deal Size: $2.7 million Upfront Cash: Undisclosed
Deal Type: Funding September 28, 2021
Details:
In pre-IND meeting request application, Company is confirming direction it plans to take in development of Ifenprodil as an adjunct to Topotecan for treatment of chemo refractory small cell lung cancer. Ifenprodil is NMDA receptor antagonist specifically targeting GluN2B.
Lead Product(s): Ifenprodil Tartrate,Topotecan Hydrochloride
Therapeutic Area: Oncology Product Name: NP-120
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2021
Details:
A precision medicine-based chemoprotective agent, ALRN-6924 is designed to selectively activate p53 in normal cells, thereby upregulating p21, which pauses cell cycle in normal cells but not in p53-mutated cancer cells.
Lead Product(s): ALRN-6924,Topotecan Hydrochloride
Therapeutic Area: Oncology Product Name: ALRN-6924
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2021
Details:
Salarius is advancing a Phase 1/2 dose-expansion clinical trial evaluating seclidemstat in combination with the chemotherapy agents topotecan and cyclophosphamide (TC) as a potential second- and third-line therapy for Ewing sarcoma, and for other FET-rearranged sarcomas.
Lead Product(s): Seclidemstat,Topotecan Hydrochloride,Cyclophosphamide
Therapeutic Area: Oncology Product Name: SP-2577
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2021
Details:
Berzosertib in combination with the chemotherapy topotecan resulted in an objective response rate (ORR) of 36% among patients with relapsed small cell lung cancer (SCLC), including durable responses among a majority of responding patients with platinum-resistant disease.
Lead Product(s): Berzosertib,Topotecan Hydrochloride
Therapeutic Area: Oncology Product Name: M6620
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2021
Details:
The data to be presented is from Aileron’s Phase 1b study, evaluating ALRN-6924 as a therapeutic agent administered ahead of chemotherapy to prevent chemotherapy-induced toxicities in patients with p53-mutated small cell lung cancer who are being treated with topotecan.
Lead Product(s): ALRN-6924,Topotecan Hydrochloride
Therapeutic Area: Oncology Product Name: ALRN-6924
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2020
Details:
Aileron intends to use the net proceeds from the transaction for general corporate purposes and extending its cash runway to support its ALRN-6924 clinical development strategy.
Lead Product(s): ALRN-6924,Topotecan Hydrochloride
Therapeutic Area: Oncology Product Name: ALRN-6924
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Lincoln Park Capital Fund
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Agreement September 21, 2020
Details:
Study is evaluating ALRN-6924 to protect against chemotherapy-induced bone marrow toxicities in patients with p53-mutated small cell lung cancer (SCLC) treated with topotecan .
Lead Product(s): ALRN-6924,Topotecan Hydrochloride
Therapeutic Area: Oncology Product Name: ALRN-6924
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
